Can You Patent Bacteriophages in the UK? Patentability, Prosecution and Regulatory Traps for Phage Therapies

The question of bacteriophage patents in the UK has moved from academic curiosity to commercial urgency. Patent-landscape analyses published in 2026 show a sharp rise in phage-related filings across both the UKIPO and EPO, driven by antimicrobial resistance (AMR) concerns and a maturing pipeline of engineered phage therapeutics. Simultaneously, the MHRA has consolidated its regulatory position on bacteriophages as biological medicinal products, and UK Parliamentary committees have taken written evidence on the IP and biobanking infrastructure needed to support phage therapy development. For R&D heads, in-house counsel and biotech founders, the window to secure meaningful patent protection, and to avoid the prosecution and regulatory traps that can hollow out that protection, is now.

Executive Summary: Five Takeaways Before You File

This guide is designed for decision-makers evaluating whether and how to file bacteriophage patents in the UK and at the EPO. It covers patentability criteria, practical claim-drafting templates, prosecution and opposition strategy, freedom-to-operate (FTO) analysis, and the MHRA regulatory framework that shapes both patent value and enforcement risk. Before diving into the detail, these five headline takeaways frame the discussion:

• Yes, bacteriophages are patentable in the UK, but only where the applicant demonstrates novelty, inventive step and sufficient disclosure beyond the naturally occurring organism.
• Engineered phages attract stronger protection than wild-type isolates. Claim drafting must differentiate the technical contribution from what nature already provides.
• MHRA classifies phage therapeutics as biological medicinal products, triggering GMP manufacturing requirements that directly affect patent scope and commercial freedom to operate.
• Opposition risk at the EPO is rising as more phage families reach grant. Preparation of robust priority evidence and sufficiency data is essential from the earliest filing date.
• FTO analysis is non-negotiable before commercialisation, patent families covering host-range specificity, delivery mechanisms and cocktail compositions create overlapping thickets that catch developers off-guard.

Industry observers expect the next 18–24 months to be decisive: companies that file strategically and engage with MHRA early are likely to build the strongest commercial positions.

Patentability of Bacteriophages in the UK

Are bacteriophages patentable in the UK? Yes, provided the standard patentability requirements under the Patents Act 1977 are met: novelty, inventive step, industrial applicability and sufficient disclosure. The critical question is not whether phages can be patented, but which claim strategies survive examination at the UKIPO and EPO, and which collapse under sufficiency or “product of nature” objections.

Phage therapy patentability turns on the distinction between discovery and invention. Under UK law, a naturally occurring substance, including a wild-type bacteriophage, is not inherently excluded from patent protection, but the applicant must show that isolating and characterising the phage produces a technical effect that was not previously available. The EPO Guidelines for Examination reinforce this principle for biological material: an isolated organism is patentable where the applicant provides an enabling disclosure demonstrating a function or application that satisfies inventive step.

Natural Phages vs Engineered Phages, When the UK and EPO Allow Protection

The distinction between natural and engineered phages is the single most important variable in phage therapy patentability. Wild-type phage isolates face heavier scrutiny. Examiners at both the UKIPO and EPO will challenge whether isolating a phage from an environmental sample, soil, sewage, clinical specimens, constitutes a sufficient technical contribution. Protection is possible, but requires detailed evidence of how the isolate was identified, its host-range specificity, and the technical problem it solves that was not solved by known phages.

Engineered bacteriophages, by contrast, offer significantly stronger footing. Genetic modifications, such as tail-fibre engineering for altered host range, introduction of payload proteins, or removal of lysogeny-associated genes, create clear technical contributions that satisfy both novelty and inventive step. Representative patent families illustrate this pattern. For example, WO2023203063A9 (linked to research at the University of Oxford’s Radcliffe Department of Medicine) claims engineered bacteriophage compositions with modified receptor-binding proteins, while GB0514324D0 covers phage-derived constructs with defined antibacterial functions. These families demonstrate that claims anchored to engineered features have a track record of progressing through prosecution.

Claim Types That Work for Bacteriophage Patents in the UK

When patenting bacteriophages, the choice of claim type directly determines both the scope of protection and the risk of challenge during prosecution or opposition. The following claim categories have demonstrated viability at the UKIPO and EPO:

• Composition/product claims. Claims to a pharmaceutical composition comprising a specified phage (or phage cocktail) with defined structural or functional features. These provide broad protection but require detailed disclosure of the phage’s characteristics and activity data.
• Medical-use claims. Purpose-limited product claims (under Article 54(5) EPC at the EPO) or second-medical-use claims directed to the treatment of a specific bacterial infection. These are particularly valuable for phage developers targeting defined clinical indications.
• Method/process claims. Claims directed to manufacturing methods, isolation, purification, formulation, or to methods of engineering phages with specified properties. These can survive even where the product itself is difficult to claim.
• Delivery and formulation claims. Claims covering the mode of administration (e.g., nebulised phage for pulmonary infections, encapsulated cocktails for gastrointestinal targets) often face fewer novelty objections and can be commercially significant.

Drafting Claims and Disclosure: UKIPO & EPO Practical Guide

Effective claim drafting for phage therapy sits at the intersection of patent law and microbiology. The core tension is breadth versus enablement: phage developers naturally want the widest possible protection, but both the UKIPO and EPO will refuse claims that exceed the disclosure. Understanding this balance is the foundation of any successful prosecution strategy for bacteriophage patents in the UK and Europe.

Sample Claim Language and Why Each Element Matters

The following three annotated claim templates illustrate the principal filing strategies. Each template is a simplified illustration, actual claims must be tailored to the specific invention and supporting data.

Template 1, Natural Isolate Composition Claim:

“A pharmaceutical composition comprising an isolated bacteriophage of the family [X], characterised by lytic activity against [target bacterial species/strain], wherein the bacteriophage comprises a genome having at least [Y]% sequence identity to SEQ ID NO: [Z], and a pharmaceutically acceptable carrier.”

This template anchors the claim to sequence identity and a defined target host, addressing both novelty (specific isolate) and sufficiency (sequence disclosure). The risk is that a narrow sequence-identity threshold limits scope, while too broad a threshold may be challenged for insufficiency.

Template 2, Engineered Phage Composition Claim:

“A recombinant bacteriophage comprising a modified tail-fibre protein, wherein said modification confers binding specificity to [target receptor] on [bacterial species], and wherein said bacteriophage further comprises a deletion of [lysogeny gene region], rendering the bacteriophage obligately lytic.”

Engineering claims are typically the strongest category. The modified tail-fibre protein and the lysogeny deletion each represent independent technical features that distance the claim from the natural state. These elements should be supported by experimental data, binding assays and genome sequencing, in the specification.

Template 3, Medical-Use Claim:

“A bacteriophage composition as defined in claim [N] for use in the treatment of [specific infection/indication] caused by [bacterial species], wherein the composition is administered [route/formulation].”

Purpose-limited product claims comply with EPO practice (Art. 54(5) EPC). The advantage is novelty over prior-art phages where the specific therapeutic use has not been disclosed; the risk is that the scope is limited to the defined indication.

Specification Drafting, Experiments, Sequences, Host-Range Data and Fallback Strategies

Sufficiency of disclosure is the single most litigated ground in phage patent prosecution and opposition. To withstand challenge, the specification should include:

• Full genome sequences deposited in a recognised database or international depositary authority under the Budapest Treaty.
• Host-range data across a panel of clinically relevant bacterial strains, demonstrating specificity and breadth of activity.
• Experimental methods for phage isolation, propagation and purification, sufficiently detailed for a skilled person to reproduce the invention.
• Fallback claim positions drafted at multiple levels of specificity (genus → species → strain; broad composition → specific cocktail → single-phage product) so that prosecution can narrow without losing commercial value.

Phage Patent Prosecution UK: Filing Routes, Timelines and Opposition Risk

Choosing the right filing route and prosecution strategy is essential for securing robust bacteriophage patents in the UK. The three principal options, UK national filing at the UKIPO, direct European filing at the EPO, and PCT application designating EP/UK, each have tactical implications for phage developers.

A UK national filing is fastest and lowest-cost for securing a priority date, and is appropriate where the UK is the primary commercial market. However, it provides protection only within the UK. A direct EP filing or PCT-to-EP route offers broader geographic coverage and allows claims to be prosecuted under EPO examination standards, which are generally well-defined for biological inventions. The PCT route has the additional advantage of deferring national-phase entry costs while preserving priority.

For phage inventions, priority filing timing is particularly sensitive. Because phage research often involves rapid discovery of new isolates and iterative engineering, it is critical to file a provisional or first application as soon as sufficient experimental data exists to support at least one enabled claim. Subsequent data, additional host-range panels, engineering modifications, in vivo efficacy, can be added through continuation-in-part filings (where available) or through divisional applications that carve out distinct claim sets from the parent.

Patent families such as WO2013024304A1, which covers phage-derived antimicrobial compositions, illustrate the value of building a family of related applications that capture successive technical improvements. Monitoring such families through prosecution and into grant is important for both defensive and offensive strategy.

Opposition Defence Checklist, Evidence, Priority and Inventive-Step Arguments

EPO phage patents that proceed to grant face a nine-month opposition window, and industry observers expect opposition activity to increase as the commercial value of phage therapeutics grows. The following checklist prepares patentees for opposition defence:

• Priority evidence. Ensure the priority document fully supports the claims as granted. Any added subject matter between priority and PCT/EP filing is a standard attack line.
• Sufficiency dossier. Compile the experimental data (host-range, sequence, activity assays) filed with the application and any post-filing evidence that may be admissible to demonstrate enablement.
• Inventive-step arguments. Identify the closest prior art and articulate the technical problem solved. For engineered phages, highlight the unpredictable nature of phage biology, that the skilled person would not have had a reasonable expectation of success in achieving the claimed modification.
• Third-party observations. Monitor for third-party observations filed during prosecution, as they often preview the arguments an opponent will deploy.
• Divisional strategy. If opposition targets specific claims, having a pending divisional application allows the patentee to pursue alternative claim sets without losing the filing date.

Freedom to Operate for Phage Therapeutics: Commercialisation Checklist

Freedom to operate (FTO) analysis is the bridge between a granted patent and a commercially viable product. For phage developers, FTO is complicated by the overlapping nature of phage patent claims, multiple families may cover the same bacterial target through different claim lenses (composition, medical use, delivery). A structured FTO process is essential before clinical trials or product launch.

The FTO checklist for phage therapeutics should cover:

• Patent family mapping. Identify all granted and pending patents claiming phages active against the target pathogen. Search by sequence, host-range, engineering feature and formulation.
• Claim analysis. For each identified family, assess whether the commercial product falls within the literal scope or doctrine-of-equivalents scope of the claims. Pay particular attention to host-range claims that may be drafted broadly.
• Licensing review. Determine whether any identified patents are available for licence, and on what terms. Material transfer agreements (MTAs) from biobanks or academic collections may impose IP obligations that flow through to commercial products.
• Biobank and collection obligations. If phages are sourced from public or institutional collections, confirm whether the provider retains rights over derivatives, and whether deposit obligations under the Budapest Treaty have been met.
• Patient-specific cocktails. For personalised phage therapy models, where cocktails are prepared on a per-patient basis, assess whether composition claims covering cocktail components create infringement risk, and whether compassionate-use exemptions apply.

Transactional and Due-Diligence Red Flags

In M&A and licensing transactions, phage-related IP due diligence must address several unique issues. Manufacturing know-how is often as valuable as the patent itself, particularly for GMP-compliant production processes. Material transfer histories should be traced to confirm clean title. Biobank deposit records must be verified to ensure they support the patent claims’ sufficiency requirements.

Regulatory Traps: MHRA Phage Guidance, GMP, Clinical Trial and Access Issues

Is phage therapy legal in the UK? Yes, but the pathway to market is tightly regulated. The MHRA has consolidated its position that bacteriophage products intended for therapeutic use in humans are classified as biological medicinal products. This classification triggers the full regulatory framework applicable to biologics: GMP-compliant manufacturing, clinical trial authorisation, and, for marketed products, a full marketing authorisation. Coverage from BioWorld confirms that this MHRA guidance has provided developers with greater regulatory clarity regarding the development and licensing requirements for phage-based medicines.

The regulatory classification has direct consequences for patent strategy. A phage product manufactured under GMP will typically require defined and reproducible production processes. Claims directed to those processes, and to the GMP-grade compositions they produce, can be more enforceable than claims to loosely defined phage isolates, because the product as marketed will match the claim language more precisely.

However, regulatory traps await the unwary. The most significant is the tension between compassionate or unlicensed use and the authorised product pathway. UK clinicians may prescribe unlicensed phage preparations under the “specials” framework for individual patients where no licensed alternative exists. This practice, while legally permissible, creates a grey zone for patent enforcement: if unlicensed phage preparations are manufactured and administered on a patient-specific basis, they may fall outside the scope of composition claims drafted for standardised products. Written evidence submitted to UK Parliamentary committees has highlighted the need for clearer frameworks around biobanking, access, and the IP implications of patient-specific phage preparation.

Interplay of Patent Rights and Regulatory Exclusivity

Supplementary Protection Certificates (SPCs) can extend the effective patent term for medicinal products to compensate for regulatory delays. For phage developers, the practical question is whether a phage therapeutic product that receives marketing authorisation will qualify for SPC protection. The answer depends on whether the active ingredient is defined with sufficient precision in both the patent claims and the marketing authorisation. Given the biological variability inherent in phage preparations, early alignment between patent claim language and the regulatory dossier product definition is critical. Engaging with the MHRA through its scientific-advice process and aligning regulatory product characterisation with patent claim terminology are recommended steps for any developer targeting SPC eligibility.

For a broader view of how to protect your intellectual property across borders, including in the life-sciences context, GLE’s cross-border IP guide offers additional context.

Litigation and Enforcement Considerations for Bacteriophage Patents in the UK

Enforcing phage patents presents distinctive challenges rooted in the biology of the inventions themselves. Claim construction, the court’s interpretation of the language defining the claimed invention, is complicated by the inherent variability of biological organisms. A composition claim that defines a phage by sequence identity may be infringed by a product containing a phage with minor sequence variations that nonetheless falls within the claimed percentage threshold. Conversely, functional claims (e.g., “a bacteriophage having lytic activity against Pseudomonas aeruginosa“) may be challenged as insufficiently precise if they encompass an unworkably large number of organisms.

Evidence collection in phage patent disputes requires specialist microbiological expertise. Proving infringement may require genomic sequencing of the competitor’s product, demonstration of functional equivalence (host-range, lytic activity), and comparison of manufacturing processes. Expert witnesses with backgrounds in phage biology and bioinformatics are essential. For guidance on international litigation strategy, including cross-border coordination, GLE’s litigation guide provides additional resources.

Cross-Border Enforcement: UK vs EU Post-Brexit

Since the UK’s departure from the EU, European patents (EP) designating the UK must be validated as UK national patents. This means that enforcement in the UK and enforcement in UPC-participating EU member states now follow parallel tracks. For phage developers holding EP-granted patents, this creates a need for coordinated enforcement strategies. An opposition at the EPO affects the European patent across all designated states, but a UK national action, either for infringement or revocation, proceeds independently. Where a competitor operates in both the UK and the EU, parallel proceedings may be necessary, increasing cost but also increasing strategic leverage.

Conclusion and Recommended Next Steps

Securing commercially valuable bacteriophage patents in the UK requires an integrated strategy that bridges patent prosecution, regulatory compliance and commercial planning. The field is moving fast: patent filing activity is rising, MHRA guidance has crystallised, and Parliamentary attention signals that policy infrastructure, including biobanking and access frameworks, is evolving. Companies that act early, file strategically and engage regulatory authorities from the outset are best positioned to build defensible portfolios. The recommended immediate steps are:

• Run a comprehensive FTO search before committing to clinical development.
• Prepare full sequence, host-range and engineering data to support the earliest possible priority filing.
• Consider an EP filing route for geographic breadth, with UK national designation secured.
• Engage experienced patent counsel for claim drafting aligned to MHRA product characterisation.
• Initiate MHRA scientific-advice dialogue to ensure patent and regulatory strategy are synchronised.

For further guidance on international intellectual property strategy or to find a specialist patent attorney, consult GLE’s international commercial guide or explore our practitioner directory.

Sources

1. PatSnap, Phage Therapy Patent Landscape (2026)
2. UK Parliament, Written Evidence on Phage Policy
3. Google Patents, Representative Phage Patent Families (WO2013024304A1, GB0514324D0, WO2023203063A9)
4. Dehns, Patenting Viruses and Phages
5. BioWorld News, MHRA Offers Clarity for Bacteriophage Development/Licensing
6. Radcliffe Department of Medicine (Oxford), Engineered Bacteriophage Publication
7. Springer Nature, Intellectual Property Issues for Bacteriophages
8. EPO Guidelines for Examination
9. MHRA, Medicines & Healthcare Products Regulatory Agency